AMPLY Secures £1.3 Million Funding for AI Drug Discovery
Revolutionizing Medical Innovation: AMPLY's Bold Funding Leap! In a groundbreaking move, Belfast-based AMPLY Discovery has secured a remarkable $1.75 million (£1.3 million) seed funding to enhance its pioneering AI-driven drug discovery platform. This funding round, led by Twin Path Ventures, with contributions from US-based Venture Science, Co-fund NI, the British Business Bank, and QUBIS Limited, sets the stage for AMPLY to tackle the pressing challenges posed by aggressive cancers and drug-resistant infections.
Founded by prominent figures in computational biology, including Dr.
Ben Thomas, AMPLY is dedicated to developing innovative gene-silencing therapies for hard-to-treat cancers like triple-negative breast cancer and acute myeloid leukaemia. Furthermore, as the threat of antimicrobial resistance (AMR) looms larger, AMPLY is committed to creating nebulized treatments for chronic lung infections, utilizing antimicrobial peptides that can penetrate directly into the lungs. This kind of proactive approach not only mitigates the risks posed by existing treatment failures but also opens up a new frontier in personalized medicine.
The true power of AMPLY's platform lies in its unique combination of artificial intelligence, next-generation sequencing, and synthetic biology. By analyzing diverse biological data, AMPLY can swiftly identify potential treatment targets and bio-print molecules that are prime for laboratory testing. With its revolutionary AMPLYfolioAI, the team is pioneering smarter biologic drugs, pushing for faster, more affordable solutions that cater to individual genetic variations. “We are deploying our platform against complex cancers and multidrug-resistant pathogens," says Dermot Tierney, Co-Founder and Chief Operating Officer at AMPLY. This investment not only reflects a vote of confidence amid a tightening fundraising landscape for seed-stage biotechs but also empowers AMPLY to pursue its mission of addressing unmet healthcare needs at scale.
Key Terms Explained
- Seed Funding
- Seed funding is the initial capital used by startups to support their business until it can generate cash on its own, or until it is ready for further investments. In this context, AMPLY Discovery received $1.75 million in seed funding.
- AI-driven Drug Discovery Platform
- AI-driven drug discovery uses artificial intelligence to aid in the discovery and development of new drugs. AMPLY Discovery uses its AI platform to swiftly identify potential treatment targets and bio-print molecules for testing.
- Venture Capital
- Venture capital is a type of private equity financing that investors provide to startups that are deemed to have high growth potential. Here, Twin Path Ventures, Venture Science, Co-fund NI, the British Business Bank, and QUBIS Limited have provided venture capital to AMPLY Discovery.
Frequently Asked Questions
- How much funding did AMPLY Discovery secure in the recent seed round?-AMPLY Discovery secured a remarkable $1.75 million (£1.3 million) in the recent seed funding round.
- What are the prime healthcare challenges that AMPLY is set to tackle?+
- Who were the primary contributors to AMPLY's seed funding round?+
- What is the primary objective of AMPLY's AI-driven drug discovery platform?+
- How is AMPLY leveraging its investment to cater to unmet healthcare needs?+
They've invested in AMPLY Discovery
Get to know these Healthtech investors
Click here for a full list of 6,908+ startup investors in the UK